CA2201967C - Acetamide derivative having defined particle size - Google Patents

Acetamide derivative having defined particle size Download PDF

Info

Publication number
CA2201967C
CA2201967C CA002201967A CA2201967A CA2201967C CA 2201967 C CA2201967 C CA 2201967C CA 002201967 A CA002201967 A CA 002201967A CA 2201967 A CA2201967 A CA 2201967A CA 2201967 C CA2201967 C CA 2201967C
Authority
CA
Canada
Prior art keywords
particles
modafinil
micrometers
diameter
median
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA002201967A
Other languages
French (fr)
Other versions
CA2201967A1 (en
Inventor
Peter E. Grebow
Vincent Corvari
David Stong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cephalon LLC
Original Assignee
Cephalon LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23240954&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2201967(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cephalon LLC filed Critical Cephalon LLC
Priority to CA002382275A priority Critical patent/CA2382275C/en
Publication of CA2201967A1 publication Critical patent/CA2201967A1/en
Application granted granted Critical
Publication of CA2201967C publication Critical patent/CA2201967C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/26Psychostimulants, e.g. nicotine, cocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Electrochromic Elements, Electrophoresis, Or Variable Reflection Or Absorption Elements (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Developing Agents For Electrophotography (AREA)
  • Adhesives Or Adhesive Processes (AREA)
  • Paints Or Removers (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Oscillators With Electromechanical Resonators (AREA)
  • Packaging For Recording Disks (AREA)
  • Laminated Bodies (AREA)
  • Slot Machines And Peripheral Devices (AREA)

Abstract

Pharmaceutical compositions comprising modafinil in the form of particles of defined size. The particle size of modafinil can have a significant effect on the potency and safety profile of the drug.

Description

MODAFINIL HAVING DEFINED Pi~RTICLE SIZE
BACKGROUND OF THE INVENTION
This invention relates to the acetamide deriva-tive modafinil. Modafinil (C15H15N02S), is 2-(benzhydryl-sulfinyl)acetamide; and is also known as 2-[(diphenyl-methyl) sulfinyl] acetamide.
Modafin.il has been described as preseriting a "neuropsychopharmacological spectrum characterized by the presence of excitation with hyperactivity and of hypermotility; and by the absence of stereotypy (except in high doses) and of potentialisation of the effects of apomorphine and amphetamine°' (U. S. Patent 4,177,290;
hereinafter the " '290 patent"). A single administration of modafinil results in increased locomotor activity in mice arid increased nocturnal activity in monkeys (Duteil et al., Eur. J. Pharmacol. 180:49 (1990)). The neuropsychopharma-cological profile of modafinil has been distinguished from that of amphetamines (Saletu et al., Int. J. Clin. Pharm.
Res. 9:183 (1989)). Modafinil is thought to modulate the central postsynaptic alphal-adrenergic receptor, without participation of the dopaminergic system (Duteil et al., supra). Modafinil has been successfully tested in humans for treatment of idiopathic hypersomnia and narcolepsy (Bastuji et al., Prop. Neuro-Psych. Biol. Psych. 12:695 (1988) ) .
Narcolepsy is a chronic disorder characterized by intermittent sleep attacks, persistent, excessive daytime sleepiness and abnormal rapid eye movement ("REM") sleep manifestations, such as sleep-onset REM periods, cataplexy, sleep paralysis and hypnagogic hal7_ucinations, or both (Assoc. of Sleep Disorders Centersl Sleep 2:1 (1979)). Most patients with narcolepsy also have disrupted nocturnal sleep (Montplaisir, in Guilleminault et al. eds., Narcolepsy, Spectrum Pub., New York, pp. ' 43-56). Pathological somnolence, whether due to narcolepsy or other causes, is disabling and potentially "
dangerous. Causes of pathological somnolence, other than narcolepsy, include chronic sleep loss (Carskadon et al., Sleep, 5:S73 (1982); Carskadon et al., Psychophysiology, 18:107 (1981)); sleep apnea (Kryger et al., Principles 1o and Practice of Sleep Medicine, W.B. Saunders Co., Philadelphia, PA (1989)); and other sleep disorders (International Classification of Sleep Disorders:
Diagnostic and Coding Manual, American Sleep Disorder Association, Rochester, MN (1990)). Whether due to 1s narcolepsy or other causes, pathological somnolence produces episodes of unintended sleep, reduced attention, and performance errors. Consequently, it is linked to a variety of transportation and industrial accidents (Mitler et al., Sleep 11:100 (1988)). A therapeutic 2o agent that reduces or eliminates pathological somnolence would have important implications not only for individual patients, but also for public health and safety. Other uses of modafinil have been presented. U.S. Patent 5,180,745 discloses the use of modafinil for providing a 25 neuroprotective effect in humans, and in particular for the treatment of Parkinson's disease. The levorotatory form of modafinil, i.e. , (-) benzhydrylsulfinyl-acetamide, may have potential benefit for treatment of depression, hypersomnia and Alzheimer's disease (U. S.
3o Patent 4,927,855). European Published Application 547952 (published June 23, 1993) discloses the use of modafinil as an anti-ischemic agent. European Published Application 594507 (published April 27, 1994) discloses the use of modafinil to treat urinary incontinence.
StTMMARY OF THE INVENTION
Our invention discloses a pharmaceutical composi-tion comprising modafinil in the form of particles of a defined size, and the use of such composition. We have discovered that the size of moclafinil particles is important to the potency and safety profile of the drug.
Thus, in a first aspect, the invention features a pharmaceutical composition compris:i.ng a substantially homogeneous mixture of modafinil particles, wherein at least about 950 of the cumulative total of modafinil particles in said composition have a diameter of less than about 200 micrometers and said composition contains between about 50 milligrams and about 700 milligrams of said modafinil.
"Particle," as used herein, refers to an aggre gated physical -unit of the acetamide compound, i.e., a piece or a grain of acetamide. For example, Figures 2-5 provide photographic representations of various modafinil particles from Lots E-D and L-1.
As used herein, the term "mean," when used in reference to the size of modafinil particles, refers to the sum of the size measurements of a;11 measurable particles measured divided by the tot~31 number of particles measured. For example, for rive measurable particles which could be measured, and were determined to have diameters of 20 microns, 23 microns, 20 microns, 35 microns and 20 microns, the mean diameter would be 23.6 microns. As used herein, the term "diameter" is a volumetric measurement based on the presumed spherical shape of modafinil particles.
As used herein, the term "median," when used in reference to the size of modafinil particles, indicates that about 50% of all measurable particles measured have 3a a particle size less than the definef. median particle size value, and that about 50% of all measurable particles measured have a particle size greater than the defined median particle size value. For example, for the five particle values listed above, the median diameter would be 20 microns.
As used herein, the term "mode:," when used in reference to the size of modafinil particles, indicates the most frequently- occurring particle size value. For example, for the five particle values listed above, the WO 96/11001 PCTlUS95/12944 mode diameter would be 20 microns.
As used herein, the term "percent cumulative,"
when used in reference to the size of .modafinil particles, refers to an aggregate of the individual s percent values for all measurable particles measured at specified diameters.
As used herein, "about" means plus or minus approximately ten percent of the indicated value, such that "about 20 microns" indicates approximately 18 to 22 1o microns. The size of the particle can be determined, e.g., by the methods provided below, and by conventional methods known to those of skill in the art.
In accordance with the invention disclosed herein, the mean particle size for a modafinil particle 1s preferably ranges from about 2 microns to about 19 microns, more preferably from about 5 microns to about 18 microns, and most preferably from about 10 microns to about 17 microns.
In accordance with the invention disclosed herein, 2o the median particle size for modafinil preferably ranges from about 2 microns to about 60 microns, more preferably from about 10 microns to 50 microns, and most preferably from about 20 microns to about 40 microns.
In accordance with the invention disclosed herein, 25 the mode particle size for modafinil preferably ranges from about 2 microns to about 60 microns, more preferably from about 10 microns to about 50 microns, and most preferably from about 20 microns to about 40 microns.
We view the median measurement as having greater 3o importance compared to the mode or mean values in that the median value provides an indication of the x distribution of the particles measured in a given population. While not necessarily a limitation but rather an indicator of the consistency of the population 3s measured, the ratio of median: mean: mode would ideally be 1:1:1; however, a ratio of median to mean of 1:2.50 to 1:0.50 is acceptable, and a ratio of median to mode of 1:2.50 to 1:0.50 is acceptable. Ideally, the standard deviation between the mean, median and mode measurements of a modafinil population would approach zero, indicating that every particle in the population measured was substantially identical or met the criteria for an ideal, normalized distribution. A standard deviation of less than about 25 between the mean, median and mode 1o measurements is acceptable as an-indication of the consistency of the population of the particles measured.
In accordance with the invention disclosed herein, it is preferable that not more than about 50 of the cumulative total (percent cumulative) of modafinil particles in any one dose provided to a mammal have particle sizes greater than about 200 microns; it is more preferable that not more than about 5% of the cumulative total (percent cumulative) of modafinil particles in any one dose provided to a mammal have particle sizes greater 2o than about 190 microns; it is most preferable that not more than about 5% of the cumulative total (percent cumulative) of modafinil particles in any one dose provided to a mammal have particle sizes greater than about 180 microns. Thus, a "substantially homogeneous 2s mixture" of modafinil particles, as utilized herein, refers to a mixture of modafinil particles in which at least about 95~ of the particles in that mixture are less than a defined size.
The value ranges defined above are based upon 3o measurements made utilizing technology and instruments ~ developed by the Hiac/Royko Division of Pacific Scientific (11801 Tech Road, Silver Spring, MD 20904, USA). As those in the art may appreciate, different instruments manufactured by different companies may 3s provide different measurements for the same particles.
For example, in a characteristic modafinil lot (Lot L-2), the mean, median, and mode particle measurements obtained using a Coulter Counter TA II sizing counter were 43, 31, and 29 microns, respectively. Using a Hiac/Royko Model 9064 sizing counter, the mean, median and mode particle measurements obtained for Lot L-2 were 18.75, 31.41 and 25.31 microns, respectively. These differences are presumably predicated upon the different approaches used in measuring particles of such diminutive sizes. Thus, 1o the value ranges provided above are relative and are most preferably to be considered in view of utilization of instruments and operating systems manufactured by Hiac/Royko, for example, and preferably, the Hiac/Royko Model 9064 system sizing counter. Modafinil.particles of the invention can be in the form of a pharmacologically acceptable salt, e.g., an acidic or basic addition salt.
In another aspect, the invention features a method of altering a somnolent state, e.g., narcolepsy, idiopathic hypersomnia and related sleep disorders, using 2o modafinil particles of a defined size. The method involves administering to a mammal a pharmaceutical composition comprising an effective amount of modafinil in the form of particles of a defined size.
"An effective amount", as used herein, is an 2s amount of the pharmaceutical composition that is effective for treating a somnolent or somnolescent state, i.e., an amount of modafinil of a defined particle size that is able to reduce or eliminate the symptoms of a somnolescent state. An effective amount of a 3o pharmaceutical composition of the invention is useful for enhancing alertness, or increasing regularity of sleep rhythms.
A "pharmaceutical composition", as used herein, means a medicament for use in treating a mammal that s5 comprises modafinil of a defined particle size prepared in a manner that is appropriate for administration to a mammal. A pharmaceutical composition according to the invention may also, but does not of necessity, include a non-toxic pharmaceutically acceptable carrier.
The pharmaceutical composition of the invention can contain at least about 50 mg, preferably at least about 100 mg, or more preferably at least about 200 mg of modafinil having a particle size as defined above. The pharmaceutical composition preferably contains no more 1o than about 700 mg; more preferably, no more than about 600 mg; and most preferably, no more than about 400 mg, of modafinil having a particle size as defined above.
Other features and advantages of the invention will be apparent from the following detailed description and from the claims.
DETAILED DESCRIPTION
We first briefly describe the drawings.
I. Drawincts Fig. 1 is a graph depicting particle size 2o distributions for six lots of modafinil: Lots L-1, L-2, E-A, E-B, E-C and E-D.
Fig. 2 is a scanning electron micrograph of a sample of modafinil Lot E-D at 50 x magnification.
Fig. 3 is a scanning electron micrograph of a sample of modafinil Lot E-D at 100 x magnification.
Fig. 4 is a scanning electron micrograph of a sample of modafinil Lot L-1 at 50 x magnification.
Fig. 5 is a scanning electron micrograph of a sample of modafinil Lot L-1 at 100 x magnification.
3o Fig. 6 is a graph depicting the dissolution rate of modafinil particles from Lot E-D (median particle size 94.05 hum) and Lot L-1 (median particle size 50.18 ;Cm).
Fig. 7 is a graph depicting the dissolution rate of modafinil particles from Lot E-B (median particle size 89.10 Vim), Lot E-D (median particle size 94.05 ;Cm) and _ g _ Lot L-1 (median particle size 50.18 ~Cm).
Fig. 8 is a graph depicting mean plasma concentration of modafinil in dogs following single oral doses of modafinil from lots with different particle sizes.
Fig. 9 is a graph depicting mean plasma concentration of modafinil equivalents, i.e., modafinil and modafinil acid metabolite, in dogs, following single oral doses of modafinil from lots with different particle to sizes.
II. The Invention The invention results from our discovery that the particle size, and the consistency of the particle size, of modafinil can have a significant effect on its potency and safety profile.
The first human trials for the use of modafinil to treat narcolepsy took place outside of the United States of America. The modafinil used in the initial studies was prepared in non-commercial scale lots (referred to 2o herein as "early" or "E" lots). Pursuant to our discovery of the present invention, it was observed that the early lots had a median particle size of between 80 microns ("~Cm") and 150 Vim. In the initial safety studies conducted outside of the United States, early lot modafinil was administered to humans without reports of clinically significant adverse events in acute administration.
Separate safety and efficacy studies of modafinil were subsequently conducted in the United States under 3o the direction of Cephalon, Inc. using modafinil lots prepared by a method scaled up for commercial production (referred to herein as "late" or "L" lots). When the late lots of modafinil were administered to humans in the United States, the initial clinical trial revealed the R'O 96/11001 PCT/US95/12944 occurrence of unanticipated adverse events at a dose . level (800mg/day) previously determined to be acceptable during studies conducted outside of the United States.
We discovered that the late lots had a median particle s size of between 30 and 50 hum. Thus, the initial human trials conducted in the United States were performed with modafinil having a significantly smaller particle size.
As was subsequently discovered, lots comprising a smaller particle size resulted in an increase in the 1o potency of modafinil, leading us to conclude that the drug can be more readily absorbed when compared to modafinil derived from lots comprising a larger particle size. Therefore, modafinil particles of a defined size provide at least two significant and unexpected 1s advantages. First, potency is increased. A smaller average particle size allows achievement of a given modafinil plasma concentration at a lower oral dose.
Second, with the knowledge of the importance of particle size on potency, the safety profile of the drug can be 2o more accurately controlled because dosing with consistent and defined particle sizes allows for greater reliability in the dosing of the drug necessary to achieve a desired result.
III. ~iuman Clinical Safety Studies - Foreign 25 The safety and pharmacodynamics of modafinil were initially characterized in several studies conducted outside the United States using modafinil obtained from the early lots. During these studies, modafinil in amounts of up to 4,500 mg have been ingested without the 30 occurrence of significant clinical side effects (see, for example, Bastuji, supra; see also Lyons, T.J. and French, J. Aviation, Space and Environmental Medicine May, 1991, 432). No statistically or clinically significant hemodynamic changes in heart rate or blood pressure in 35 patients or in healthy volunteers using modafinil doses tested in the foreign studies have been reported.
IV. Human Clinical Safety Studies - United States While significant testing of modafinil had already been conducted outside the United States, new drug s candidates, such as modafinil, typically undergo clinical research in the United States in order to corroborate the information obtained in foreign studies. The first United States clinical evaluation of modafinil was a double-blind, ascending dose study involving oral 1o administration of modafinil to healthy males (i.e., physically and mentally healthy male subjects 18 to 50 years of age; average body weight of -10% to +15% of normal weight for age, height, frame and sex; 2101).
The planned doses for the first United States 15 clinical trial were 200, 400, 600, 800, 1000, 1200 and 1400 mg/day of modafinil or placebo. These dose levels were based upon the safety profile observed during the foreign clinical testing of modafinil. Subsequent doses were given only when it was determined that the 2o previously administered dose was safe and well tolerated.
For example, the safety data for the 200 mg study dose was reviewed and assessed before other volunteers received the 400 mg dose.
In this first United States Phase I clinical 2s study, modafinil from Lot L-1 was utilized. Complete data were obtained for three of the seven modafinil dose levels intended for testing, i.e., 200, 400, and 600 mg/day. However, elevations in heart rate and blood pressure were noted in two of the volunteers at the 800 30 mg dose level. These symptoms resolved without treatment or sequelae following drug discontinuation. This was surprising and completely unexpected, given the escalation of modafinil dosing observed in the foreign studies. Because these results were unexpected and ~- 11 -because they occurred in healthy volunteers, these . adverse events led to discontinuation of dosage progression at the 1000, 1200 and 1400 mg/day levels until the cause of such results was determined.
V. Discrepancy Between the Foreign and United States Results In searching for the cause of the discrepancy, we compared plasma levels of modafinil measured in the first United States study and the preceding foreign studies.
to We found that at a given oral dose, when compared to subjects in the foreign studies, subjects in the United States study had higher peak modafinil plasma levels.
The modafinil tablets used in the foreign studies were based upon early lots of modafinil, while the is modafinil tablets used in the United States study were based upon late lots of modafinil. We theorized that a difference in bioavailability of the different lots of modafinil was responsible for the differences in maximum tolerable dose observed in the foreign and United States 2o clinical studies. Although not obvious or readily apparent, one of several possible explanations which we posited was a possible difference in the modafinil particle size used in the foreign and the United States studies.
25 VI. Particle Size Analysis Following this assumption, we compared various parameters from lots of the bulk drug; such comparisons had not been conducted previously, given the assumption that the modafinil being tested in the United States was 3o the "same" as that investigated outside of the United States. Particle size distribution of the bulk drug was among the parameters examined. We have performed modafinil particle size analyses with a Hiac/Royko Model WO 96/11001 PCT/US9~/12944 9064 sizing counter, a Coulter Counter sizing counter, by optical microscopy and by scanning electron microscopy.
Our particle size measurements were obtained using ' a Hiac/Royco Model 9064 sizing counter following manufacturer instructions (400 ~m aperture; saturated water with modafinil solution; PDAS program). A summary of the results of these measurements is presented in Table 1, which includes the mean, median and mode particle sizes for six representative lots of modafinil.
to For comparative purposes, the standard deviation values derived from the mean, median and mode measurements are provided, as are the ratio values of median: mean: mode.
Lots E-A, E-B, E-C and E-D were among the so-called early lots, and Lots L-1 and L-2 were among the so-called late lOtS .

Table 1 MODAFINIL PARTICLE DIAMETER
I~OT MEAN* MEDIAN* MODE* STD MEDIAN:

(/gym) (gym) (um) DEVIATION MEAN:MO

BETWEEN DE

MEAN, MEDIAN, MODE

E-A 34.60 143.65 176.48 74.27 1:4.15:

+/- 5.21 +/- 3.26 +/-5.32 .g1 E-B 29.99 89.10 78.59 31.53 1:2.97:

+/-1.09 +/-4.28 +/- 2.60 1.13 E-C 28.27 79.00 101.00 37.30 2:2.79:

+/- 4.10 +/- 3.78 +/- 40.92 ,7g E-D 22.14 94.05 158.63 68.28 1:4,25:

+/- 0.76 +/- 13.75 +/- 63.81 .59 I~-1 21.40 50.18 56.56 18.73 1:2.34:

+/- 2.52 +/- 12.57 +/- 22.39 .89 L-2 18.75 31.41 25.31 6.36 1:1.68:

+/- 1.89 +/- 3.57 +/- 1.34 1.24 *n=4; +/- alues standard deviations v are Fig. 1 is a graph of particle diameter versus percent cumulative particles for late Lots L-1, L-2, and for the early Lots E-A, E-B, E-C, and E-D. The 50 percent cumulative particle size for Lots L-1 and L-2 was between approximately 30 ~cm and approximately 50 ~cm, while the 50 percent cumulative particle size for Lots E-A, E-B, E-C, and E-D was between approximately 80 ~m and approximately 140 ;Cm.
In addition to the Hiac/Royko data, electron 2o microscopy and optical microscopy were used to verify modafinil particle size and morphology. Representative scanning electron micrographs of early Lot E-D are shown in Fig. 2 (50x magnification) and in Fig. 3 (100x magnification). Representative scanning electron micrographs of late Lot L-1 are shown in Fig. 4 (50x magnification) and Fig. 5 (100x magnification).
SUBSTITUTE SHEET (RULE 26) It is noted that the size of modafinil particles may be determined by any of several conventional methods.
Methods useful for analyzing particle size within the range of 100 Angstroms to 100 ~Cm, include, but are not limited to: laser diffraction particle size analysis, mechanical sieving, optical microscopy, ultracentrifugation, sedimentation, air permeability, electron microscopy, scanning electron microscopy and Coulter Counter techniques. For a general review of 1o methods for determining particle size, see Martin et al., Physical Pharmacy, 3rd Ed., Lea & Febiger, Philadelphia (1983). See also O~Conner in Remington~s, infra., Section IX.
Optical microscopy is useful for particle size 1s measurement in the range of 0.2 ~Cm to 100 ~Cm. For optical microscopy, an emulsion or suspension, diluted or undiluted, is mounted on a slide or ruled cell. The microscope eyepiece is fitted with a micrometer by which the size of the particles may be estimated.
2o Mechanical sieving uses a series of standard sieves calibrated by the National Bureau of Standards.
Mechanical sieves may be used for screening material as fine as 44 ~m (No. 325 sieve). Sieves manufactured by photo-etching and electroforming are available with 25 apertures from 90 ~cm to 5 Vim.
Measurements obtained using instruments and techniques developed by Hiac/Royko are preferred. A
Hiac/Royco sizing counter utilizes the principle of light-extinction (obscuration) for particle size 3o detection. The principle involved is that when a particle suspended in a liquid passes through a sensor microcell where a laser beam is directed through a window at the cell, the particles in the fluid block the laser beam from a light-extinction photodiode (photodetector) 3s resulting in a loss of light intensity. This loss of light intensity detected by the photodetector produces an electrical pulse for each particle. These pulses are proportional in amplitude to the light. intensity (light extinction) which is a measure of particle size.
VII. Effect of Modafinil Particle Size on Rate of Modafinil Dissolution We investigated the effect of modafinil particle size on the rate of dissolution. The results of those experiments are summarized in Fig. 6 and Fig. 7.
to In the first experiment,-500 ml of deionized water was put in a 1-liter beaker and 50 mg of E-D or L-1 was added. The suspension was stirred constantly with a 5 cm Teflon-coated magnetic stir bar and a magnetic stir plate (Thermolyne model # 546725). Samples of 1 ml each were taken at times 0, 1, 5, 10, 15, 20, 25, 30, 40, 50, and 60 minutes, with each sample being replaced with 1 ml of deionized water. The stir plate speed setting was "2"
for the first 20 minutes, and "7" from 20 to 60 minutes.
Each sample was immediately filtered through a 0.45~Cm 2o filter, to remove undissolved particles. The filtered samples were assayed for modafinil, by high performance liquid chromatography, based upon the method of Moachon et al. (J. Chromatag. B 654:91 (1994)). Modafinil Lot L-1 (median: 50.18 ~tm) had a faster dissolution rate than did modafinil Lot E-D (mean: 94.05 Vim). The results of the first experiment are summarized in Fig. 6.
A second dissolution rate experiment was conducted to determine relative dissolution rates of modafinil from the capsules used in the dog study (described below) of 3o plasma modafinil levels following oral administration of modafinil from Lots E-B, E-D and L-1. In the second dissolution rate experiment, the solvent was 900 ml of 0.01 N HC1, maintained at 37°C. Each sample placed into the solvent consisted of 200 mg of modafinil packed in a gelatin capsule. Stainless steel coils were attached to the capsules to prevent them from floating. A stirring paddle was used at 100 rpm. Solution samples were taken at 0, 5, 10, 15, 20, 25, 30, 40 and 60 minutes. The ' results of the modafinil capsule dissolution experiment s are summarized in Fig. 7. ' VIII. Effect of Modafinil Particle Size on Modafinil Plasma Concentration Given the disparity in results between the foreign and United States studies using what was presumed to be "identical" modafinil, additional non-human analyses were necessary prior to continuation of human clinical trials.
Accordingly, animal studies in dogs were carried out to determine the in vivo pharmacokinetics of modafinil with different average particle size diameters, roughly designated as having "small" (Lot L-1) and "large" (Lots E-B and E-D) median particle sizes. Nine male dogs were randomly assigned, according to body weight to three dose groups. Each group was given a single oral dose of 200 of mg modafinil weekly for three weeks in a randomized, 2o cross-over design, as described in Table 2.
Table 2 GROUP NUMBER OF WEEK BULK DRUG LOT AND
DOGS MEDIAN PARTICLE SIZE
1 3 1 E-D (94.05 ~.Cm) 2 L-1 (50.18 /,6m) 3 E-B ( 8 9 .10 hum ) 2 3 1 L-1 (50.18 Vim) 2 E-B ( 8 9 .10 /gym ) 3 E-D (94.05 /.gym) 3 3 1 E-B ( 8 9 . 10 ~Cm ) 2 E-D (94.05 Vim) 3 L-1 (50.18 Vim) After each weekly dose, blood samples (2 ml) were drawn from all animals by venepuncture predose (within one hour of dosing), and at 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 18, 24, and 36 hours post-dose. Blood samples were collected in heparinized (lithium heparin) test tubes and centrifuged at 2,500 to 3,000 rpm. The plasma was drawn off with a glass pipette, and stored frozen (-20 C) until analyzed. The plasma concentration of modafinil, and its acid and sulfone metabolites were simultaneously determined by high-pressure liquid chromatography, according to the method of Moachon et al. (J. Chromatag.
l0 B 654:91 (1994)).
Mean plasma modafinil levels in the nine dogs, at 0 to 36 hours after modafinil administration, are depicted in Fig. 8. With "small" particles (Lot L-1), the plasma modafinil concentration peaked at 10 ~,g/ml.
In Contrast. with "laraer'~ nart'_i c~ c~~ fT~nt~ F-T7 nr F-R1 _ _ ____-__-_, __-___ _~_'__ r~_ _-_-__ '__~- ~. ... ~~ ~" .,.~ , the plasma modafinil concentration peaked at 8 ~g/ml.
Thus, the modafinil having a median particle size of 50.18 ~m resulted in a higher peak plasma concentration than that obtained with the same dose of modafinil 2o administered in the form of larger particles. Similar results were observed regarding the acid metabolite of modafinil, 2-benzhydrylsulfinylacetic acid as depicted in Fig. 9.
These results implicated the consequences of different particle sizes and the importance of controlling modafinil particle size. By controlling the particle size, safety concerns can be addressed. For example, a non-homogenous mixture of modafinil particle sizes may not provide consistent potency nor avoid 3o undesired fluctuations in plasma modafinil concentrations; such fluctuations can lead to undesired and unexpected events. Moreover, the use of modafinil particles having a defined size is more efficient because a given plasma modafinil concentration can be achieved at a lower oral dose.

After the discrepancy between the foreign and first United States studies was resolved and determined to be related to the differences in particle sizes, a second Phase I study was conducted in the United States, to further determine the clinical safety, tolerance and ' pharmacokinetic properties of modafinil having a particle size as defined. The second study involved normal young males and an experimental design similar to the first United States study (described above).
to In the second study, all subjects began at 200 mg/day using modafinil from Lots L-1 or L-2. Dosage was then titrated, in 200 mg/day increments, up to the target dose. The results of this study suggested that 600 mg/day was the maximum tolerable dose ("MTD") of modafinil, with 800 mg/day being the minimum intolerable dose.
IX. Methods of Preparing Modafinil Havina Defined Size Modafinil and modafinil-related compounds can be 2o prepared by conventional methods. Methods for preparing modafinil and modafinil-related compounds appears in the '290 patent. Modafinil of the particle size defined herein may be obtained by a variety of approaches utilizing conventional methods, e.g., the methods 2s disclosed in the '290 patent, and then subjecting the modafinil of undefined particle size to conventional methods of milling and sieving. Methods for comminution (i.e., the mechanical process of reducing the size of particles or aggregates) are known to those in the art.
3o Examples are provided in O'Conner et al. Chpt. 88, Remington's Pharmaceutical Sciences, 18th Edition, Mack Publishing Co., Easton, PA (1990). Following comminution, the particles can be separated into a series of sieve cuts by passing the particles downward through an agitated vertical stack of sieves of decreasing mesh sizes and collecting the granules retained on each sieve or in the bottom pan. Particles which fall outside of a desired range canagain be subjected to milling and s sieving.
X. Formulation and Administration An appropriate dosage for modafinil having a defined particle size is between about 50 mg and about 700 mg of modafinil.
to The pharmaceutical composition described herein is most preferably administered orally in the form of a vehicle such as a tablet, capsule, powder, pill, liquid/suspension or emulsion. The administration vehicle may comprise a pharmaceutically- acceptable 15 carrier. The carrier may comprise agents that aid solubility, absorption, flavor, color or texture of the vehicle or its contents. Topical administration via an epidermal patch or the like, or administration via direct injection of the drug, is also acceptable. A vehicle of 2o the invention can include ~10-15% of the modafinil particle, due to factors such as vehicle manufacturing tolerances and expected shelf life of the modafinil. For example, a vehicle labeled as containing 50 mg can be initially prepared with, e.g., 55 or 58 mg of modafinil, 2s with the expectation that after one month to two years of storage, the active amount of modafinil therein has decreased. Vehicles prepared with such adjustments in order to compensate for the expected degradation of the drug fall within the scope of the invention.
3o While the invention has been described in considerable detail, the invention disclosed herein is not to be limited to the actual description, but is to be afforded the full scope of the appended claims and all equivalents thereto. Although the specific examples 3s presented herein are directed to the use of modafinil of a defined particle size in the mediation of narcolepsy, other uses of modafinil (e.g. , for treatment of Parkinson's disease, urinary incontinence, Alzheimer's ' disorder, etc.) have been presented in the art, and those utilities are appropriate in conjunction with the invention as disclosed herein.

Claims (28)

1. A pharmaceutical composition comprising a substan-tially homogeneous mixture of modafinil particles, wherein at least about 95% of the cumulative total of modafinil particles in said composition have a diameter of less than about 200 micrometers and said composition contains between about 50 milligrams and about 700 milligrams of said modafinil.
2. The composition of claim 1, wherein said particles have a median diameter of between about 2 micrometers and about 60 micrometers.
3. The composition of claim 1, wherein particles have a mean diameter of from about 2 micrometers to about 19 micrometers.
4. The composition of claim 1, wherein said particles have a mode diameter of from about 2 to about 60 micrometers.
5. The composition of claim 1, wherein the ratio of the median diameter of said particles to the mean diameter of said particles is in the range 1:2.50 to 1:0.50.
6. The composition of claim 1, wherein the ratio of the median diameter of said particles to the mode diameter of said particles is in the range 1:2.50 to 1:0.50.
7. The composition of claim 1, wherein said particles have a mean diameter of from about 2 micrometers to about 19 micrometers, a median diameter of from about 2 micrometers to about 60 micrometers, and a mode diameter of from about 2 micrometers to about: 60 micrometers, the ratio of said median diameter to said mode diameter being in the range 1:2.50 to 1:0.50 and the ratio of said median diameter to said mean diameter being in the range 1:2.50 to 1:0.50.
8. The composition. of claim 7, wherein the standard deviation of said mean, median and mode diameters is less than 25 micrometers.
9. The composition of any one of claims 1 to 9, in a form adapted for oral administration being a tablet, capsule, powder, pill, liquid suspension or emulsion.
10. The use of a substantially homogeneous mixture of modafinil particles whereof at least about 95% of the cumulative total of raid particles have a diameter of less than about 200 micrometers for the manufacture of a pharmaceutical composition containing between about 50 mg and about 700 mg of modafinil for use in altering the somnolent state of a mammal.
11. The use of claim 14, wherein said somnolent state is narcolepsy.
12. The use of modafinil for the manufacture of a pharmaceutical composition comprising modafinil particles having a median particle size of about 2 to about 60 micrometres for use in altering the somnolent state of a mammal, wherein said composition contains 50 to 700 milli-grams of said modafinil particles.
13. Use as claimed in claim 12, wherein particles have a mean diameter of from about 2 micrometers to about 19 micrometers.
14. Use as claimed in claim 12, wherein said particles have a mode diameter of from about 2 to about 60 micrometers.
15. Use as claimed in claim 12, wherein the ratio of the median diameter of said particles to the mean diameter of said particles is in the range 1:2.50 to 1:0.50.
16. Use as claimed in claim 12, wherein the ratio of the median diameter of said particles to the mode diameter of said particles is in the range 1:2.50 to 1:0.50.
17. Use as claimed in claim 12, wherein said particles have a mean diameter of from about 2 micrometers to about 19 micrometers, a median diameter of from about 2 micrometers to about 60 micrometers, and a mode diameter of from about 2 micrometers to about 60 micrometers, the ratio of said median diameter to said mode diameter being in the range 1:2.50 to 1.:0.50 and the ratio of said median diameter to said mean diameter being in the range 1:2.50 to 1:0.50.
18. The use of modafinil for the manufacture of a pharmaceutical composition comprising modafinil particles having a mean particle size of about 2 to about 19 micrometres for use in altering the somnolent state of a mammal, wherein said composition contains 50 to 700 milligrams of said modafinil particles.
19. Use as claimed in claim 18, wherein said particles have a mode diameter of from about 2 to about 60 micrometers.
20. Use as claimed in claim 18, wherein the ratio of the median diameter of said particles to the mean diameter of said particles is in the range 1:2.50 to 1:0.50.
21. Use as claimed in claim 18, wherein the ratio of the median diameter of said particles to the mode diameter of said particles is in the range 1:2.50 to 1:0.50.
22. The use of modafinil for the manufacture of a pharmaceutical composition comprising modafinil particles have a mode particle size of about 2 to about 60 micrometers for use in altering the somnolent state of a mammal, wherein said composition contains 50 to 700 milligrams of said modafinil particles.
23. Use as claimed in claim 22, wherein the ratio of the median of said particles to the mean diameter of said particles is in the range 2:2.50 to 1:0.50.
24. Use as claimed in claim 22, wherein the ratio of the median diameter of said particles to the mode diameter of said particles is in the range 1:2.50 to 1:0.50.
25. Use as claimed in any one of claims 12 to 24, wherein the standard deviation of said mean, median and mode diameters is less than 25 micrometers.
26. Use as claimed in any one of claims 12 to 25, wherein said composition is in a form adapted for oral administration, said form being a tablet, capsule, powder, pill, liquid suspension or emulsion.
27. The use of a substantially homogeneous mixture of modafinil particles whereof at least about 95% of the cumulative total of said particles have a diameter of less than about 200 micrometers for the manufacture of a pharmaceutical composition containing 50 mg to 700 mg of modafinil for use in altering the somnolent state of a mammal.
28. Use as claimed in any one of claims 12 to 28, wherein said somnolent state is narcolepsy.
CA002201967A 1994-10-06 1995-10-04 Acetamide derivative having defined particle size Expired - Lifetime CA2201967C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA002382275A CA2382275C (en) 1994-10-06 1995-10-04 Modafinil having defined particle size

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US08/319,124 1994-10-06
US08/319,124 US5618845A (en) 1994-10-06 1994-10-06 Acetamide derivative having defined particle size
US08/319,124(CON) 1994-10-06
PCT/US1995/012944 WO1996011001A1 (en) 1994-10-06 1995-10-04 Modafinil having defined particle size

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA002382275A Division CA2382275C (en) 1994-10-06 1995-10-04 Modafinil having defined particle size

Publications (2)

Publication Number Publication Date
CA2201967A1 CA2201967A1 (en) 1996-04-18
CA2201967C true CA2201967C (en) 2002-12-10

Family

ID=23240954

Family Applications (2)

Application Number Title Priority Date Filing Date
CA002382275A Expired - Lifetime CA2382275C (en) 1994-10-06 1995-10-04 Modafinil having defined particle size
CA002201967A Expired - Lifetime CA2201967C (en) 1994-10-06 1995-10-04 Acetamide derivative having defined particle size

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CA002382275A Expired - Lifetime CA2382275C (en) 1994-10-06 1995-10-04 Modafinil having defined particle size

Country Status (34)

Country Link
US (2) US5618845A (en)
EP (3) EP1088549B1 (en)
JP (1) JP2915146B2 (en)
KR (1) KR100249360B1 (en)
AT (3) ATE188607T1 (en)
AU (1) AU703087B2 (en)
BG (1) BG62952B1 (en)
BR (1) BR9509257A (en)
CA (2) CA2382275C (en)
CZ (1) CZ291700B6 (en)
DE (3) DE69520161T2 (en)
DK (3) DK0731698T3 (en)
EE (1) EE9700082A (en)
ES (3) ES2142499T3 (en)
FI (1) FI121454B (en)
GB (1) GB2293103B (en)
GR (2) GR3033152T3 (en)
HK (3) HK1003561A1 (en)
HU (1) HU226411B1 (en)
IS (1) IS1987B (en)
LT (1) LT4303B (en)
LV (1) LV11852B (en)
MD (1) MD970143A (en)
MX (1) MX9602176A (en)
NO (1) NO318818B1 (en)
NZ (1) NZ295869A (en)
PL (1) PL181523B1 (en)
PT (3) PT1088549E (en)
RO (1) RO118928B1 (en)
RU (1) RU2287987C2 (en)
SI (1) SI9520106B (en)
SK (1) SK283632B6 (en)
UA (1) UA42023C2 (en)
WO (1) WO1996011001A1 (en)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA71629C2 (en) * 1999-08-03 2004-12-15 Lilli Icos Llc Composition containing free drug particulate form of ?-carboline (variants), method for its manufacture (variants), and method for treating sexual dysfunction
US6821975B1 (en) 1999-08-03 2004-11-23 Lilly Icos Llc Beta-carboline drug products
US6346548B1 (en) 1999-08-16 2002-02-12 Cephalon, Inc. Compositions including modafinil for treatment of attention deficit hyperactivity disorder and multiple sclerosis fatigue
US6455588B1 (en) 1999-08-20 2002-09-24 Cephalon, Inc. Compositions including modafinil for treatment of eating disorders and for appetite stimulation
FR2804322B1 (en) * 2000-01-31 2002-04-19 Lafon Labor USE OF MODAFINIL FOR THE MANUFACTURE OF A MEDICINAL PRODUCT FOR CORRECTING VIGILANCE DISORDERS ASSOCIATED WITH MYOPATHIES
US20010034373A1 (en) * 2000-02-09 2001-10-25 Matthew Miller Low dose modafinil for enhancement of cognitive function
US6492396B2 (en) 2000-05-16 2002-12-10 Cephalon, Inc. Substituted thioacetamides
EP2168946A1 (en) * 2000-07-27 2010-03-31 Teva Pharmaceutical Industries Ltd Crystalline form of modafinil, and methods of preparing the crystalline form
US6919378B2 (en) * 2000-10-11 2005-07-19 Cephalon, Inc. Pharmaceutical solutions of modafinil compounds
US6489363B2 (en) * 2000-10-11 2002-12-03 Cephalon, Inc. Pharmaceutical solutions of modafinil compounds
ATE417608T1 (en) * 2000-10-11 2009-01-15 Cephalon Inc MEDICINAL COMPOSITIONS CONTAINING MODAFINIL COMPOUNDS
EA005591B1 (en) * 2000-10-11 2005-04-28 Сефалон, Инк. Compositions comprising modafinil compounds
US7704975B2 (en) * 2000-12-19 2010-04-27 Cephalon, Inc. Modafinil compound and cyclodextrin mixtures
US7141555B2 (en) 2000-12-19 2006-11-28 Cephalon, Inc. Modafinil compound and cyclodextrin mixtures
US20080058424A1 (en) * 2002-05-23 2008-03-06 Cephalon, Inc. Novel pharmaceutical formulations of modafinil
IL158959A (en) * 2001-05-25 2010-06-30 Cephalon Inc Solid pharmaceutical formulations comprising modafinil
US7576133B2 (en) 2002-03-11 2009-08-18 Carl Henry Lawyer Methods and compositions for nasal administration of modafinil
US7229644B2 (en) * 2002-05-23 2007-06-12 Cephalon, Inc. Pharmaceutical formulations of modafinil
WO2004004692A1 (en) * 2002-07-08 2004-01-15 Ranbaxy Laboratories Limited Processes for the preparation of oral dosage formulations of modafinil
US20040048931A1 (en) * 2002-07-12 2004-03-11 Craig Heacock Modafinil pharmaceutical compositions
CN1684666A (en) * 2002-07-25 2005-10-19 兰贝克赛实验室有限公司 Processes for the preparation of oral dosage formulations of modafinil
US6992219B2 (en) 2002-08-09 2006-01-31 Cephalon France Modafinil polymorphic forms
US20040116532A1 (en) * 2002-09-13 2004-06-17 Craig Heacock Pharmaceutical formulations of modafinil
US20040138180A1 (en) * 2002-10-03 2004-07-15 Barr Laboratories, Inc. Bisphosphonate composition and process for the preparation thereof
IL153098A0 (en) * 2002-11-26 2003-06-24 Chemagis Ltd Pharmaceutical compositions containing modafinil
CA2420180A1 (en) * 2003-02-28 2004-08-28 Bernard Charles Sherman Tablets comprising modafinil
CA2519117C (en) * 2003-03-17 2010-03-02 Neurohealing Pharmaceuticals, Inc. High potency dopaminergic treatment of neurological impairment associated with brain injury
US20040253308A1 (en) * 2003-04-29 2004-12-16 Barr Laboratories, Inc. Surface-treated modafinil particles
ATE442352T1 (en) * 2003-05-16 2009-09-15 Cephalon France METHOD FOR PRODUCING MODAFINIL
US7368591B2 (en) 2003-09-19 2008-05-06 Cephalon France Process for enantioselective synthesis of single enantiomers of modafinil by asymmetric oxidation
US20050137264A1 (en) * 2003-12-22 2005-06-23 Patel Ashish A. Modafinil compositions
EP2292213A1 (en) 2004-02-06 2011-03-09 Cephalon, Inc. Compositions comprising a polymorphic form of armodafinil
US20060024370A1 (en) * 2004-07-29 2006-02-02 Cephalon France Modafinil oral lyophilizate
GT200600008A (en) * 2005-01-18 2006-08-09 FORMULATION OF DIRECT COMPRESSION AND PROCESS
EP1909573A4 (en) * 2005-07-21 2010-09-22 Neurohealing Pharmaceuticals I Rapid onset and short term modafinil compositions and methods of use thereof
EP1951197A4 (en) * 2005-11-10 2011-12-21 Alphapharm Pty Ltd Process to control particle size
JP2009543803A (en) * 2006-07-12 2009-12-10 エラン・ファルマ・インターナショナル・リミテッド Modafinil nanoparticle formulation
CA2660565C (en) * 2006-08-14 2012-10-09 Neurohealing Pharmaceuticals, Inc. Modafinil-based treatment for premature ejaculation
US20080181966A1 (en) * 2006-10-18 2008-07-31 Cephalon, Inc. Modafinil pharmaceutical compositions
WO2008074097A1 (en) 2006-12-21 2008-06-26 Alphapharm Pty Ltd Pharmaceutical compound and composition
US8173169B2 (en) * 2007-07-11 2012-05-08 Hikma Pharmaceuticals Formulation and process for the preparation of modafinil
US20090325999A1 (en) * 2008-06-27 2009-12-31 Jie Du Personalized pharmaceutical kits, packaging and compositions for the treatment of allergic conditions
CN102105427A (en) * 2008-07-25 2011-06-22 阿尔法制药有限公司 Atovaquone with a particle size diameter range (D90) of greater than 3 [mu]m to about 10 [mu]m
US20100036164A1 (en) * 2008-08-06 2010-02-11 Srinivas Areveli Preparation of armodafinil form i
EP2238973A1 (en) 2009-04-07 2010-10-13 Cephalon France Lyophilized preparations of proteasome inhibitors
FR2987267B1 (en) * 2012-02-28 2015-01-16 Debregeas Et Associes Pharma APPLICATION OF MODAFINIL IN THE TREATMENT OF SUBSTITUTION OF CACANOMANES
FR2987265B1 (en) * 2012-02-28 2014-02-28 Debregeas Et Associes Pharma PHARMACEUTICAL COMPOSITION IN THE FORM OF MODAFINIL-BASED SYRUP, METHOD FOR PRODUCING THE SAME AND APPLICATION THEREOF
FR2987266B1 (en) * 2012-02-28 2014-12-19 Debregeas Et Associes Pharma PROCESS FOR OBTAINING A PHARMACEUTICAL COMPOSITION BASED ON MODAFINIL, PHARMACEUTICAL COMPOSITION THUS OBTAINED AND ITS APPLICATION
US10058542B1 (en) 2014-09-12 2018-08-28 Thioredoxin Systems Ab Composition comprising selenazol or thiazolone derivatives and silver and method of treatment therewith

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4002718A (en) * 1974-10-16 1977-01-11 Arnar-Stone Laboratories, Inc. Gelatin-encapsulated digoxin solutions and method of preparing the same
FR2408345A1 (en) * 1976-11-30 1979-06-08 Besins Jean Louis NEW COMPOSITION WITH ANTI-CONCEPTIONAL ACTION
US4122157A (en) * 1977-03-04 1978-10-24 Richardson-Merrell Inc. Nitrofurantoin sustained release tablet
GB1584462A (en) * 1977-03-31 1981-02-11 Lafon Labor N-diaryl-malonamide and diarylmethyl-sulphinyl-acetamide derivatives and pharmaceutical compositions containing them
IT1130924B (en) * 1980-03-06 1986-06-18 Secifarma Spa PROCEDURE FOR THE PREPARATION OF MICRONIZED SPIRONOLACTONE
US4600614A (en) * 1983-09-12 1986-07-15 The Dow Chemical Company High-frequency heatable plastics
US4713246A (en) * 1984-03-19 1987-12-15 Bristol-Myers Company Etoposide oral dosage form
IT1187751B (en) * 1985-10-15 1987-12-23 Eurand Spa PROCEDURE FOR THE PREPARATION OF SOLID FORMULATIONS OF NIFEDIPINE WITH HIGH BIO AVAILABILITY AND WITH PROLONGED EFFECT AND FORMULATIONS SO OBTAINED
FR2593809B1 (en) * 1986-01-31 1988-07-22 Lafon Labor BENZHYDRYLSULFINYLACETAMIDE, PROCESS FOR PREPARATION AND THERAPEUTIC USE
DE3720493A1 (en) * 1987-06-20 1989-01-26 Nattermann A & Cie MEDICINAL PREPARATIONS WITH MICRONIZED EBSELEN CRYSTALS
FR2627696B1 (en) * 1988-02-26 1991-09-13 Fournier Innovation Synergie NEW GALENIC FORM OF FENOFIBRATE
JP2642486B2 (en) * 1989-08-04 1997-08-20 田辺製薬株式会社 Ultrafine particle method for poorly soluble drugs
FR2663225B1 (en) * 1990-06-14 1994-11-04 Lafon Labor NEW USE OF MODAFINIL.
FR2684875B1 (en) * 1991-12-13 1995-05-24 Lafon Labor USE OF MODAFINIL FOR THE MANUFACTURE OF A MEDICAMENT HAVING AN ANTI-ISCHEMIC EFFECT.
FR2697162B1 (en) * 1992-10-23 1995-01-13 Lafon Labor Use of modafinil for the manufacture of a medicament for the treatment of urinary incontinence and urethro vesical sphincter disorders.
FR2702968B1 (en) * 1993-03-23 1995-06-23 Lafon Labor Process for the preparation of particles containing an active ingredient by extrusion and lyophilization.
CA2159904C (en) 1993-04-05 2000-10-10 Malcolm Bicknell Mcinnes Percussion drilling improvements
FR2706767B1 (en) * 1993-06-22 1995-09-08 Lafon Labor
FR2708201B1 (en) * 1993-06-30 1995-10-20 Lafon Labor Use of acetamide derivatives for the manufacture of medicaments.
US5493146A (en) 1994-07-14 1996-02-20 Vlsi Technology, Inc. Anti-fuse structure for reducing contamination of the anti-fuse material

Also Published As

Publication number Publication date
GR3033152T3 (en) 2000-08-31
FI971417A (en) 1997-04-04
WO1996011001A1 (en) 1996-04-18
EP1088549A1 (en) 2001-04-04
BG101389A (en) 1997-12-30
KR100249360B1 (en) 2000-04-01
LT4303B (en) 1998-03-25
FI971417A0 (en) 1997-04-04
LT97060A (en) 1997-10-27
PT731698E (en) 2000-05-31
GR3035451T3 (en) 2001-05-31
NO971541L (en) 1997-06-04
HU226411B1 (en) 2008-11-28
SK283632B6 (en) 2003-11-04
EP0731698A1 (en) 1996-09-18
ATE188607T1 (en) 2000-01-15
PL181523B1 (en) 2001-08-31
DK1088549T3 (en) 2008-11-17
DK0731698T3 (en) 2000-05-08
JP2915146B2 (en) 1999-07-05
US5618845A (en) 1997-04-08
ATE199216T1 (en) 2001-03-15
EP0966962B1 (en) 2001-02-21
UA42023C2 (en) 2001-10-15
SI9520106A (en) 1998-02-28
BG62952B1 (en) 2000-12-29
EP0966962A1 (en) 1999-12-29
HUT77778A (en) 1998-08-28
MD970143A (en) 1998-12-31
FI121454B (en) 2010-11-30
AU3951495A (en) 1996-05-02
CA2201967A1 (en) 1996-04-18
DE69535786D1 (en) 2008-08-21
EP1088549B1 (en) 2008-07-09
AU703087B2 (en) 1999-03-18
DE69514497T2 (en) 2000-08-10
JPH09511754A (en) 1997-11-25
CA2382275A1 (en) 1996-04-18
BR9509257A (en) 1998-07-07
ATE400260T1 (en) 2008-07-15
EP0731698B1 (en) 2000-01-12
ES2308960T3 (en) 2008-12-16
CZ291700B6 (en) 2003-05-14
NZ295869A (en) 1998-02-26
NO971541D0 (en) 1997-04-04
SK44597A3 (en) 1997-09-10
HK1003561A1 (en) 1998-10-30
DE69520161T2 (en) 2001-08-02
LV11852B (en) 1998-03-20
MX9602176A (en) 1997-05-31
USRE37516E1 (en) 2002-01-15
HK1024625A1 (en) 2000-10-20
DE69514497D1 (en) 2000-02-17
CA2382275C (en) 2003-12-16
IS4451A (en) 1997-03-24
RU2287987C2 (en) 2006-11-27
CZ103297A3 (en) 1997-09-17
EE9700082A (en) 1997-10-15
GB2293103B (en) 1997-05-07
ES2142499T3 (en) 2000-04-16
GB9524328D0 (en) 1996-01-31
ES2156457T3 (en) 2001-06-16
PT1088549E (en) 2008-09-23
IS1987B (en) 2005-02-15
DE69520161D1 (en) 2001-03-29
LV11852A (en) 1997-10-20
HK1034676A1 (en) 2001-11-02
NO318818B1 (en) 2005-05-09
SI9520106B (en) 2003-12-31
PT966962E (en) 2001-06-29
RO118928B1 (en) 2004-01-30
GB2293103A (en) 1996-03-20
PL319480A1 (en) 1997-08-04
DK0966962T3 (en) 2001-03-19

Similar Documents

Publication Publication Date Title
CA2201967C (en) Acetamide derivative having defined particle size
AU2014227473B2 (en) A Novel Formulation of Metaxalone
Yadav et al. Dual coating of swellable and rupturable polymers on Glipizide loaded MCC pellets for pulsatile delivery: Formulation design and in vitro evaluation
AU2007264418A1 (en) Methods for the preparation of biologically active compounds in nanoparticulate form
CA2491317C (en) Modafinil pharmaceutical compositions
WO2018034627A1 (en) Pharmaceutical composition of antidiabetic tablet
AU729586B2 (en) Modafinil having defined particle size
RU2171674C2 (en) Modafinil with specified particle size
Limpa et al. Comparative Evaluation of Bromhexine HCl Mucoadhesive Microspheres Prepared by Anionic, Cationic and Nonionic Polymers
Parashar et al. Formulation And Characterization Of Combination Drug Microspheres For Diabetes Mellitus Management
JP2023530580A (en) Nanoparticulate composition
Rajam et al. GLIPIZIDE LOADED FLOATING MICROSPHERE: FORMULATION AND EVALUATION
Hiremath Formulation and Evaluation of Microcapsules for Controlled Release of Anti Diabetic Drug by Ionotropic Gelation Technique
shukla VermaPrincipal et al. FORMULATION DESIGN, DEVELOPMENT AND EVALUATION OF FLOATING MICROSPHERE

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20151005